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Abstract
Background: The association between modulation of detailed lipoprotein profiles and cholesterol ester transfer
(CET) activity by peroxisome proliferator-activated receptor (PPAR)-a agonists in patients with coronary artery
disease remains unclear. We assessed lipid profiles, plasma CET activity, and in-stent intimal hyperplasia after
fenofibrate treatment in patients who underwent elective coronary stenting.
Methods: Forty-three consecutive patients who underwent elective coronary stenting were randomized to the
fenofibrate group (300 mg/day for 25 weeks, n = 22) or the control group (n = 21). At baseline and follow up, CET
activity and lipoprotein profiles were measured, and quantitative coronary angiography was performed.
Results: In the fenofibrate group, the levels of large very low-density lipoprotein cholesterol, and small low-density
lipoprotein (LDL) cholesterol decreased and those of small high-density lipoprotein (HDL) cholesterol increased.
Besides, CET activity decreased independent of the effect of fenofibrate on total and LDL cholesterol. The reduction
of CET activity significantly correlated with the increase in LDL particle size (r = 0.47, P = 0.03) and the decrease of
triglycerides in large HDL subclasses (r = 0.48, P = 0.03). Although there were no significant differences in
restenosis parameters between the two groups, low CET activity significantly correlated with the inhibition of
neointimal hyperplasia (r = 0.56, P = 0.01).
Conclusions: Fenofibrate inhibited CET activity and thereby improved atherogenic lipoprotein profiles, and
reduced intimal hyperplasia after coronary stenting.
Background
Fibrates, which act as peroxisome proliferator-activated
receptor (PPAR)-a agonists, are widely used in the treat-
ment of atherogenic dyslipidemia. These drugs reduce
triglycerides, raise high-density lipoprotein (HDL) cho-
lesterol, and improve the small, dense low-density lipo-
protein (LDL) phenotype [1]. Several clinical trials have
demonstrated the therapeutic efficacy of fibrates in
reducing cardiovascular events in patients with dyslipi-
demia, which predominates in patients with type 2 dia-
betes and metabolic syndrome [2-4].
Cholesterol ester transfer protein (CETP) plays an
important role in lipoprotein metabolism, including
transfer of cholesteryl ester and triglycerides between
HDL and apolipoprotein B (apoB)-containing lipopro-
teins [5]. CETP inhibition leads to increased levels of
HDL cholesterol, which contributes to prevent the
initiation and progression of atherosclerosis. Indeed,
CETP inhibitors have been investigated for clinical use
[6,7], although controversy has also arisen [8]. CETP
inhibition also results in an increase of anti-inflamma-
tory and anti-oxidative properties of HDL conferred by
apoA-1, paraoxonase 1 and platelet activating factor-
acetylhydrolase [9-11]. These findings suggest CETP
inhibition could be the target of treatment to prevent
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fibrates increased lipoprotein lipase activity and
decreased plasma cholesterol ester transfer (CET) activ-
ity in subjects with hypertriglyceridemia and in human
CETP transgenic mice [12-15]. However, the association
between modulation of lipoproteins and CET activity by
fenofibrate regarding the initiation and progression of
atherosclerosis remains unclear.
Nowadays, in-stent restenosis remains a critical pro-
blem despite the use of newly developed drug-eluting
stents [16]. Until recently, several trials using fibrates
have been conducted [2-4]; however, few studies have
reported a reduction of the occurrence of in-stent reste-
nosis [17]. We have demonstrated that fenofibrate ame-
liorates early inflammatory responses, resulting in
reduced neointimal hyperplasia after coronary stenting
in a porcine model [18]. PPAR-a inhibits the expression
of proinflammatory genes in a ligand-dependent manner
[19,20]. In animal models, PPAR-a also inhibits intimal
hyperplasia by inhibiting vascular cell recruitment and
smooth muscle cell proliferation [21,22]. These results
indicated the potential efficacy of fenofibrate in prevent-
ing in-stent intimal hyperplasia. In this study, we
assessed the lipoprotein profile, CET activity, and in-
stent intimal hyperplasia before and after fenofibrate
treatment in patients who underwent elective coronary
stenting.
Methods
Subjects
The subjects were 43 prospectively enrolled patients who
underwent elective percutaneous coronary stenting at
Juntendo University Hospital. Patients were randomized
to the fenofibrate group (300 mg/day for 25 weeks, n =
22) or the control group (n = 21) after diagnostic coron-
ary angiography. Randomization was undertaken to
match the two groups for age, gender, body mass index
(BMI), baseline lipid profiles, and presence of diabetes
mellitus. All patients were instructed to follow the Amer-
ican Heart Association Step II diet. Fenofibrate treatment
was initiated a week before coronary stenting. Before and
after treatment, lipoprotein profiles and CET activity
were assessed. Repeated coronary angiography was per-
formed at baseline, just after coronary stenting and 24
weeks after coronary stenting (25-week treatment). We
excluded patients with acute coronary syndrome,
ongoing congestive heart failure, liver dysfunction and/or
renal dysfunction. The study protocol was approved by
the ethical committee of our hospital and all the patients
gave their informed consent in writing.
Blood sampling and biochemical analyses
Plasma samples were obtained immediately before cor-
onary angiography after overnight fasting, both at
baseline and after treatment. Plasma levels of total cho-
lesterol, triglycerides, HDL cholesterol, HbA1c, and
high-sensitivity C-reactive protein (hs-CRP) were mea-
sured by standard methods; LDL cholesterol levels were
calculated by Friedewald’s formula as previously
described [23]. CET activity was measured using com-
mercially available CETP activity assay kits (BioVision
Inc, Mountain view, CA). Briefly, the CETP activity
assay kit uses a donor molecule that contains a fluores-
cent self-quenched neutral lipid that is transferred to an
acceptor molecule in the presence of CETP. CETP-
mediated transfer of the fluorescent neutral lipid to the
acceptor molecule results in an increased fluorescence.
The value for HbA1c (%) is estimated as an NGSP
equivalent value (%) calculated by the formula HbA1c
(%) = HbA1c (JDS) (%) + 0.4%, considering the rela-
tional expression of HbA1c (JDS) (%) measured by the
previous Japanese standard substance and measurement
methods and HbA1c (NGSP) [24].
Analysis of lipoprotein profiles
Cholesterol and triglyceride profiles in plasma lipopro-
teins were analyzed using the LipoSEARCH system,
which is a dual-detection high performance liquid chro-
matography (HPLC) system with two tandem-connected
TSKgel LipopropakXL columns (300 × 7.8-mm; Tosoh,
Japan), at Skylight Biotech Inc. (Akita, Japan), as we and
others have previously described [25,26]. We obtained
the cholesterol and triglyceride levels in 20 lipoprotein
subclasses according to lipoprotein particle diameter. To
simplify the data analysis, we grouped some of the sub-
classes to yield the following 13 subclass categories: chy-
lomicron (peak 1: > 90 nm and 2: 75 nm), large very
low-density lipoprotein (VLDL) (peak 3: 64 nm, 4: 53.6
and 5: 44.5 nm), medium VLDL (peak 6: 36.8 nm),
small VLDL (peak 7: 31.3 nm), large LDL (peak 8: 28.6
nm), medium LDL (peak 9: 25.5 nm), small LDL (peak
10: 23.0 nm), very small LDL (peak 11: 20.7 nm, 12:
18.6 nm and 13: 16.7 nm), very large HDL (peak 14:
15.0 nm and 15: 13.5 nm), large HDL (peak 16: 12.1
nm), medium HDL (peak 17: 10.9 nm), small HDL
(peak 18: 9.8 nm), and very small HDL (peak 19: 8.8 nm
and 20: 7.6 nm). The average particle diameter (nm) of
LDL was obtained from the LDL peak time by HPLC.
Angiographic methods
Coronary angiography and bare metal implantation were
performed according to standard methods [27]. After
intracoronary injection of isosorbide dinitrate, angio-
grams were obtained in 2 or more views. The technical
aspects of the procedure, including the choice of bare
stent and balloon, duration of inflation and pressure,
were determined by each operator. Cardiac imaging sys-
tem (Cardiovascular Angiography Analysis System,
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tative coronary angiography (QCA) analysis. A techni-
cian without any knowledge of the study results
performed all the QCA analyses. The absolute values for
the mean reference diameter and minimal luminal dia-
meter (MLD) were determined. Percent diameter steno-
sis (MLD/reference), late lumen loss (MLD post minus
MLD at follow-up), and loss index (late lumen loss/
acute gain) were calculated. We obtained data from 19
patients in each group.
Statistical analysis
The primary objective of the study was to assess the
effect of fenofibrate on in-stent intimal hyperplasia,
including minimal luminal diameter, diameter stenosis,
and late lumen loss at the follow-up angiography. The
secondary objectives were the effects on angiographic
stenosis defined as a diameter stenosis ≥ 50% at the fol-
low-up angiography as determined by QCA analysis;
CET activity; and changes in lipid profiles defined by
HPLC analysis. Data are presented as the mean ± SD.
Statistical differences between the two groups were ana-
lyzed by unpaired Student’s t-test and chi-square test.
Statistical differences between baseline and post-treat-
ment values were analyzed by paired Student’s t-test.
Correlation between two parameters was determined by
simple linear regression analysis. The statistical analysis
was performed using StatView software (Version 5.0 for
Windows, SAS Institute, Cary, NC). The level of statisti-
cal significance was set at P < 0.05.
Results
Patient characteristics at baseline and after treatment
The characteristics of the patients at baseline and follow
up are shown in Table 1. There were no significant dif-
ferences in age, gender, BMI, lipid profiles, HbA1c, hs-
CRP, CET activity, prevalence of diabetes mellitus and
hypertension, and smoking history between the two
groups at baseline. Besides, there were no significant dif-
ferences between the two groups in the number of
patients taking other medications, such as b-blockers
(52 vs. 41%), calcium channel blockers (38 vs. 59%),
angiotensin II receptor blockers (19 vs. 9%), angiotensin
converting enzyme inhibitors (29 vs. 18%), statins (48 vs.
32%) or oral hypoglycemic drugs (19 vs. 18%) through-
out the study period. Total and LDL cholesterol levels
decreased by 9.5% (P = 0.01) and 12.5% (P =0 . 0 1 )i n
the control group and by 9.5% (P = 0.02) and 13.5% (P
= 0.02) in the fenofibrate group. There were no signifi-
cant differences in total and LDL cholesterol levels
between the two groups at follow up. Fenofibrate treat-
ment resulted in a decrease of triglyceride levels by
32.1% (P < 0.0001) and an increase of HDL cholesterol
levels by 8.7% (P = 0.03) whereas no change in
triglyceride or HDL cholesterol levels occurred in the
control group. There were no significant changes in
BMI, HbA1c or hs-CRP in either group. CET activity
decreased by 30.5% in the fenofibrate group (P < 0.05)
but it remained unchanged in the control group.
Effect of fenofibrate on lipoprotein subclass profiles
Table 2 shows the changes in lipoprotein profiles ana-
lyzed by HPLC after treatment. Fenofibrate significantly
decreased cholesterol levels in the chylomicron, large
and medium VLDL subclasses, whereas the control
group showed a significant decrease of cholesterol levels
in the medium and small VLDL subclasses. Fenofibrate
also significantly decreased cholesterol levels in the
medium, small and very small LDL subclasses, however,
there were no significant changes of cholesterol levels in
any LDL subclass in the control group. In addition,
fenofibrate significantly increased cholesterol levels in
the medium, small and very small HDL subclasses and
significantly decreased very large HDL cholesterol levels.
On the contrary, the control group showed a significant
increase of cholesterol levels in the very large and large
HDL subclasses. Fenofibrate significantly reduced trigly-
ceride levels in all lipoprotein subclasses except in the
small and very small HDL subclasses. At follow up, no
significant changes were noted in triglyceride levels in
any lipoprotein in the control group.
The LDL particle size increases as CET activity is reduced
by fenofibrate
As shown in figure 1A, after fenofibrate treatment the
mean LDL particle size increased (25.7 ± 0.6 vs. 26.1 ± 0.2
nm, P < 0.001). Despite the significant decrease in each
LDL cholesterol level observed in the two groups, the
mean LDL particle size did not change in the control
group (25.8 ± 0.7 vs. 25.8 ± 0.6 nm, NS). Figure 1B shows
that the increase in mean LDL particle size significantly
correlated with the decrease in CET activity in all patients.
Reduction of CET activity correlates with the decrease of
triglycerides in larger HDL subclasses
Figure 2 shows the significant, positive correlation
between the reduction of CET activity and the decrease
of triglyceride levels in very large and large HDL sub-
classes. This correlation was stronger in the fenofibrate
group (r = 0.48, P = 0.03). These results suggest that the
reduction of CET activity by fenofibrate may inhibit
transfer of triglycerides from apoB-containing lipopro-
tein to larger HDL subclasses.
Reduction of CET activity by fenofibrate correlates with
that of in-stent intimal hyperplasia
Table 3 shows the angiographic characteristics of
patients in the two groups. There were no significant
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groups at baseline, immediately after stenting or at fol-
low up. There were no significant differences in resteno-
sis parameters, such as restenosis rate, minimal luminal
diameter, diameter stenosis, late lumen loss, and loss
index, between the two groups. However, significant
correlations were observed between CET activity and
various lipid profiles in the study subjects, especially in
the fenofibrate group, as mentioned above. Therefore, to
investigate the effect of the reduction of CET activity on
in-stent intimal hyperplasia, patients in the fenofibrate
group were divided into the High CET activity (n = 9)
and the Low CET activity (n = 10) groups defined as
the upper and lower 50
th percentile of CET activity at
follow up. CET activity in the High CET activity group
was higher than that in the Low CET activity group
(85.5 ± 22.4 vs. 30.6 ± 23.2 pmol/μL/h, P < 0.001). The
patients in the Low CET activity group had a signifi-
cantly larger minimum lumen diameter, lower % dia-
meter stenosis, less late lumen loss, and lower loss index
at follow up than patients in the High CET activity
group or control group. Figure 3 indicates that after
fenofibrate treatment CET activity showed a significant
positive correlation with % diameter stenosis (r = 0.56,
P = 0.01).
Discussion
PPAR-a agonists reduce the production of atherogenic
large VLDL in the liver through the stimulation of fatty
acid oxidation and enhance triglyceride degradation in
VLDL through the induction of lipoprotein lipase [1].
This reduction of large VLDL subsequently results in a
decrease of small, dense LDL particles and an increase
of HDL cholesterol [1]. In addition, PPAR-a inhibits the
expression of proinflammatory genes in a ligand-depen-
dent manner by inhibiting the action of NF-B [19,20].
In animal models, PPAR-a also inhibits intimal hyper-
plasia by inhibiting vascular cell recruitment and smooth
muscle cell proliferation [21,22]. Furthermore, several
studies showed that PPAR-a agonists decreased CET
activity in subjects with hypertriglyceridemia [12-14].
However, the association between the modulation of
detailed lipoprotein profiles and CET activity by PPAR-a
agonists in patients with coronary artery disease remains
unclear. Therefore, we focused on the association of
CET activity regulated by PPAR-a agonist, fenofibrate,
with the detailed lipoprotein profiles and the develop-
ment of in-stent restenosis.
T r a n s c r i p t i o no ft h eC E T Pg e n ei si n d u c e db yah i g h
cholesterol diet in CETP transgenic mice, suggesting
that fibrates may reduce CET activity through a
decrease in cholesterol levels [28,29]. In our study popu-
lation, however, only fenofibrate treatment significantly
decreased CET activity although similar reductions of
total and LDL cholesterol levels were observed in both
groups. In addition, absolute changes in total and LDL
cholesterol levels did not correlate with CET activity.
The binding of PPAR-a to a potential peroxisome pro-
liferator response element in the promoter region of
CETP inhibited CETP gene expression [30]. These find-
ings suggest that PPAR-a agonists directly regulated, at
least in part, CET activity independent of their effects
on cholesterol lowering. HPLC analysis revealed that
fenofibrate significantly decreased cholesterol levels in
larger VLDL subclasses and smaller LDL subclasses and
increased cholesterol levels in smaller HDL subclasses.
Table 1 Characteristics of the study population at baseline and at follow up (25 weeks of treatment)
Baseline Follow up
Control
(n = 21)
Fenofibrate
(n = 22)
P Control
(n = 21)
Fenofibrate
(n = 22)
P
Age (years) 64 ± 8 67 ± 7 0.33 - - -
Male gender (%) 16 (76) 18 (82) 0.65 - - -
Diabetes mellitus (%) 6 (29) 6 (27) 0.92 - - -
Hypertension (%) 11 (52) 11 (50) 0.88 - - -
Current smoker (%) 5 (24) 6 (27) 0.80 - - -
Body mass index (kg/m
2) 24.5 ± 2.5 23.7 ± 1.9 0.27 24.3 ± 2.4 23.9 ± 2.4 0.65
Total cholesterol (mg/dL) 199 ± 33 189 ± 31 0.33 180 ± 38* 171 ± 31* 0.44
Triglycerides (mg/dL) 110 ± 48 106 ± 39 0.75 102 ± 41 72 ± 37† 0.02
HDL cholesterol (mg/dL) 45 ± 11 46 ± 10 0.84 46 ± 11 50 ± 12* 0.34
LDL cholesterol (mg/dL) 110 ± 29 102 ± 24 0.32 96 ± 33* 88 ± 27* 0.40
HbA1c (%)
hs-CRP (mg/L)
6.1 ± 1.4
1.33 ± 1.26
6.3 ± 1.6
1.93 ± 2.03
0.54
0.41
6.0 ± 1.3
1.63 ± 2.19
6.2 ± 1.7
1.75 ± 3.56
0.66
0.93
CET activity (pmol/μL/h) 88.4 ± 40.7 82.6 ± 50.4 0.68 94.4 ± 59.4 57.4 ± 35.1* 0.02
Data are presented as the mean ± SD. LDL = Low-density lipoprotein, HDL = High-density lipoprotein, hs-CRP = high sensitivity C-reactive protein, CET =
cholesterol ester transfer. Statistical differences between the control group and the fenofibrate group were analyzed by unpaired Student’s t-test. Statistical
differences between values at baseline and at follow up were analyzed by paired Student’s t-test. * P <0 . 0 5a n d† P < 0.01 Baseline vs. Follow up.
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cholesterol levels, also could be associated with a
decrease in CET activity.
Reduction of triglycerides in apoB-containing lipopro-
teins by fibrates leads to an increase in LDL particle size
[1]. In this study, however, the decrease in triglyceride
levels in any VLDL, LDL and HDL subclass was not sig-
nificantly correlated with changes in LDL size. Interest-
ingly, the change in CET activity significantly correlated
w i t ht h ei n c r e a s ei nm e a nL D Lp a r t i c l es i z ea n dt h e
decrease in cholesterol levels in smaller LDL subclasses.
Changes in CET activity also correlated with triglyceride
levels in larger HDL subclasses, which are the most car-
dioprotective HDL subclasses [23,31,32]. The reduction
of CET activity results in the inhibition of the triglycer-
ide flux from apoB containing lipoprotein to HDL.
These large and triglyceride-poor HDL have a longer
half-life in plasma than small and triglyceride-rich HDL
[1]. Therefore, fenofibrate may inhibit removal of these
cardioprotective HDL particles from the circulation
through the inhibition of CET activity.
Finally, we investigated the relationship between CET
activity and in-stent neointimal hyperplasia after coron-
ary stenting. We found no significant differences in
Table 2 Effect of fenofibrate on lipoprotein subclass profiles analyzed by HPLC in patients with CAD
Baseline Follow up
Control
(n = 21)
Fenofibrate
(n = 22)
P Control
(n = 21)
Fenofibrate
(n = 22)
P
Cholesterol
Chylomicron-C (mg/dL) 0.9 ± 0.6 0.8 ± 0.6 0.54 0.7 ± 0.6 0.5 ± 0.4† 0.20
Large VLDL-C (mg/dL) 20.7 ± 6.7 20.5 ± 7.2 0.93 17.8 ± 6.3 16.1 ± 6.4† 0.41
Medium VLDL-C (mg/dL) 16.0 ± 5.0 13.8 ± 3.8 0.11 13.3 ± 4.9* 11.9 ± 3.3* 0.28
Small VLDL-C (mg/dL) 9.4 ± 2.6 8.5 ± 2.2 0.23 8.1 ± 2.4* 8.3 ± 2.2 0.72
Large LDL-C (mg/dL) 20.5 ± 4.7 19.8 ± 3.8 0.60 18.4 ± 5.3 19.1 ± 4.6 0.68
Medium LDL-C (mg/dL) 27.2 ± 6.2 26.9 ± 6.0 0.91 25.0 ± 8.2 23.4 ± 6.0* 0.47
Small LDL-C (mg/dL) 19.5 ± 5.0 19.7 ± 5.5 0.88 17.9 ± 6.9 15.9 ± 4.4† 0.27
Very small LDL-C (mg/dL) 14.3 ± 4.1 15.2 ± 4.6 0.48 13.2 ± 5.4 12.2 ± 3.2† 0.49
Very large HDL-C (mg/dL) 4.1 ± 1.2 4.7 ± 1.5 0.14 4.6 ± 1.8* 3.9 ± 1.5* 0.18
Large HDL-C (mg/dL) 7.4 ± 3.9 8.5 ± 4.1 0.37 8.8 ± 4.6* 7.1 ± 4.2 0.21
Medium HDL-C (mg/dL) 12.3 ± 3.4 12.0 ± 3.3 0.80 12.4 ± 3.4 15.4 ± 4.4† 0.02
Small HDL-C (mg/dL) 9.8 ± 2.4 9.3 ± 2.4 0.51 9.8 ± 2.1 11.9 ± 2.8† 0.009
Very small HDL-C (mg/dL) 7.0 ± 1.1 7.3 ± 1.8 0.46 6.9 ± 1.2 8.8 ± 1.8† < 0.001
Triglycerides
Chylomicron-TG (mg/dL) 1.9 ± 1.4 1.7 ± 1.5 0.68 1.7 ± 2.1 0.9 ± 1.0† 0.14
Large VLDL-TG (mg/dL) 22.3 ± 4.4 26.2 ± 11.5 0.15 23.7 ± 12.4 15.1 ± 9.5† 0.01
Medium VLDL-TG (mg/dL) 9.7 ± 2.3 11.0 ± 4.6 0.25 10.1 ± 4.0 7.4 ± 3.7† 0.03
Small VLDL-TG (mg/dL) 4.6 ± 1.0 5.1 ± 2.0 0.30 4.9 ± 1.7 3.8 ± 1.7† 0.05
Large LDL-TG (mg/dL) 6.3 ± 1.5 6.6 ± 2.0 0.54 6.3 ± 2.0 5.7 ± 2.1* 0.37
Medium LDL-TG (mg/dL) 7.2 ± 1.7 7.6 ± 1.8 0.42 6.9 ± 2.1 6.8 ± 2.2* 0.86
Small LDL-TG (mg/dL) 5.4 ± 1.3 6.1 ± 1.7 0.13 5.1 ± 1.7 5.1 ± 1.6† 0.99
Very small LDL-TG (mg/dL) 5.0 ± 1.2 5.9 ± 1.9 0.09 4.8 ± 1.7 4.6 ± 1.6† 0.68
Very large HDL-TG (mg/dL) 1.8 ± 0.4 1.8 ± 0.4 0.90 1.9 ± 0.6 1.2 ± 0.5† < 0.001
Large HDL-TG (mg/dL) 2.6 ± 1.1 2.9 ± 1.2 0.40 3.3 ± 1.5 1.5 ± 1.0† < 0.001
Medium HDL-TG (mg/dL) 4.2 ± 1.3 4.3 ± 1.2 0.77 4.5 ± 1.3 3.5 ± 1.5* 0.03
Small HDL-TG (mg/dL) 3.5 ± 1.1 3.7 ± 0.9 0.56 3.6 ± 0.9 3.5 ± 1.5 0.89
Very small HDL-TG (mg/dL) 3.2 ± 0.7 3.6 ± 0.8 0.07 3.2 ± 0.7 3.2 ± 1.2 0.95
Data are presented as the mean ± SD. CAD = coronary artery disease, VLDL = Very low-density lipoprotein, LDL = Low-density lipoprotein, HDL = High-density
lipoprotein, -C = -cholesterol, -TG = -triglycerides, Statistical differences between the control group and the fenofibrate group were analyzed by unpaired
Student’s t-test. Statistical differences between values at baseline and at follow up were analyzed by paired Student’s t-test. * P <0 . 0 5a n d† P < 0.01 Baseline vs.
Follow up.
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follow up (gray bar). Bars represent the mean ± SD. (B) Correlation between mean LDL particle size and cholesterol ester transfer (CET) activity
at baseline and at follow up in the control (white circle) group and fenofibrate (gray circle) group.
Figure 2 Correlation between triglyceride levels in very large (A) and large (B) HDL subclasses and cholesterol ester transfer (CET)
activity at baseline and at follow up in the control (white circle) group and fenofibrate (gray circle) group.
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and the control group at follow up. However, patients in
the Low CET activity subgroup showed a significant
lower % diameter stenosis and loss index than patients
in the High CET activity subgroup and the control
group. Interestingly, CET activity at follow up showed a
significant correlation with % diameter stenosis while
there were no significant correlations between lipopro-
tein profiles and angiographic findings. As we and
another group have previously demonstrated, arterial
injury induces inflammatory responses that play impor-
tant roles in the occurrence of neointimal hyperplasia at
the site of coronary stenting [18,26,33]. CETP inhibition
increases apoA-1, paraoxonase 1 and platelet activating
factor-acetylhydrolase on HDL, which have anti-inflam-
matory and antioxidative properties [9-11]. Furthermore,
in this study, the reduction of CET activity was asso-
ciated with a decrease of small LDL that is highly sus-
ceptible to oxidation [23]. We speculate that fenofibrate
Table 3 Lesions and procedural characteristics at the time of intervention and follow-up angiography
Control
(n = 19)
Fenofibrate
(n = 19)
P Fenofibrate
High CET activity
(n = 9)
Low CET activity
(n = 10)
P
Target vessel
LAD (%) 6 (42) 5 (24) 0.49 2 (20) 3 (27) 0.93
LCX (%) 3 (21) 6 (29) 3 (30) 3 (27)
RCA (%) 5 (36) 10 (48) 5 (50) 5 (46)
Complex lesion (%) 14 (74) 10 (53) 0.18 6 (67) 4 (44) 0.34
Restenosis lesion (%) 3 (16) 3 (16) 1.00 1 (11) 2 (20) 0.60
Before stenting
Reference diameter (mm) 2.67 ± 0.51 2.61 ± 0.53 0.73 2.72 ± 0.61 2.60 ± 0.39 0.61
Minimal lumen diameter (mm) 0.44 ± 0.15 0.55 ± 0.20 0.10 0.59 ± 0.21 0.53 ± 0.18 0.55
Diameter stenosis (%) 82.8 ± 6.1 78.2 ± 8.6 0.09 77.4 ± 9.4 78.6 ± 8.8 0.78
Lesion length (mm) 11.8 ± 4.3 13.4 ± 6.2 0.40 12.9 ± 6.1 13.8 ± 6.8 0.78
Procedural data
Maximum balloon pressure (atm) 12.9 ± 4.7 12.3 ± 4.8 0.68 12.3 ± 4.9 12.6 ± 4.8 0.80
Balloon to vessel ratio 1.13 ± 0.21 1.16 ± 0.17 0.63 1.17 ± 0.17 1.16 ± 0.18 0.88
Stent segment length (mm) 13.6 ± 3.8 13.5 ± 3.8 0.90 14.3 ± 5.0 13.2 ± 2.7 0.56
Immediately after stenting
Minimal lumen diameter (mm) 2.79 ± 0.65 2.56 ± 0.50 0.26 2.56 ± 0.39 2.56 ± 0.59 1.00
Diameter stenosis (%) 9.4 ± 10.8 10.5 ± 12.8 0.79 9.7 ± 9.5 11.2 ± 15.4 0.80
Follow-up
Minimal lumen diameter (mm) 1.57 ± 0.56 1.64 ± 0.60 0.73 1.35 ± 0.62 1.90 ± 0.46 0.04
Diameter stenosis (%) 44.3 ± 19.4 38.6 ± 22.0 0.44 51.9 ± 21.6 26.6 ± 14.8* 0.01
Late lumen loss (mm) 1.22 ± 0.51 0.91 ± 0.64 0.15 1.21 ± 0.61 0.64 ± 0.56* 0.05
Loss index
Restenosis (%)
0.52 ± 0.23
5 (26)
0.44 ± 0.29
4 (21)
0.39
0.70
0.60 ± 0.28
3 (33)
0.29 ± 0.23*
1 (10)
0.02
0.21
Data are mean ± SD. CET = cholesterol ester transfer. LAD = left anterior descending coronary artery, LCX = left circumflex coronary artery, RCA = right coronary
artery. The high CET activity and low CET activity were defined as the upper and lower 50
th percentile of CET activity levels at follow-up, respectively. Complex
lesion was defined as lesion type B2 and C according to the American College of Cardiology/American Heart Association grading system. Statistical differences of
parameters between each group were analyzed by unpaired Student’s t-test. *P < 0.05 and **P < 0.01 vs. control group.
Figure 3 Correlation between % diameter stenosis and
cholesterol ester transfer (CET) activity at follow up.
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Page 7 of 9prevents in-stent neointimal hyperplasia through a
reduction of CET activity and the subsequent induction
of anti-inflammatory and antioxidative lipoprotein
profiles.
This study has several limitations. First, the sample
size was small, especially in the High and Low CET
activity groups. Therefore, we could not perform multi-
variate analysis to exclude the interaction among lipo-
protein subclasses, CET activity and angiographic
findings. We believe that the present study is one of the
pioneering and valuable reports promoting further
investigations. Second, we could not exclude the effects
of changes in triglycerides and HDL cholesterol induced
by fenofibrate from those on CET activity. However,
there were no significant correlations between changes
in CET activity and changes in total triglycerides or
HDL cholesterol. Third, we did not measure CETP mass
in this population. Therefore, whether the reduction of
CET activity depends on the production of CETP
remains unclear. Fourth, all patients were performed
bare metal but not drug-eluting stenting. However, as
mentioned above, in-stent restenosis still remains a clin-
ical problem even in drug-eluting stent era [16]. In addi-
tion, we did not perform intravascular ultrasound for
quantitative assessment in this study. The assessment
using intravascular ultrasound is needed in the next
step.
Conclusions
In conclusion, fenofibrate decreased CET activity inde-
pendent of its lowering effect on total and LDL choles-
terol in patients with coronary artery disease. That
reduction of CET activity significantly correlated with
any increase in LDL particle size and a decrease in tri-
glycerides in larger HDL subclasses, besides a decrease
in in-stent intimal hyperplasia. Inhibition of CET activity
by fenofibrate might be a potent strategy for preventing
in-stent intimal hyperplasia after coronary stenting.
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